Prostate Cancer

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. January 24, 2022

Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. January 24, 2022

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. January 24, 2022

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. January 24, 2022

A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. January 24, 2022

Hematuria Following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Follow-Up. January 24, 2022

PCaGuard: A Software Platform to Support Optimal Management of Prostate Cancer. January 21, 2022

Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection. January 21, 2022

Active surveillance for intermediate-risk prostate cancer. January 21, 2022

Transrectal Ultrasound-Guided Biopsy Should Continue to Be a Standard of Care for The Detection of Prostate Cancer. January 21, 2022

Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States. January 21, 2022

MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer. January 20, 2022

Supportive care needs of men with prostate cancer: A systematic review update. January 20, 2022

Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. January 20, 2022

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. January 20, 2022

Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8. January 20, 2022

Examination of prostate-specific antigen (PSA) screening in military and civilian men: analysis of the 2018 behavioral risk factor surveillance system. January 19, 2022

Value of T2 Mapping MRI for Prostate Cancer Detection and Classification. January 19, 2022

Diagnostic performance of fusion (US/MRI guided) prostate biopsy: propensity score matched comparison of elastic versus rigid fusion system. January 19, 2022

A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. January 19, 2022

Page 1 of 1200

email news signup